GHRH Receptor Antagonists Show Promise in Slowing Prostate Cancer Progression

Prostate cancer is a significant health concern, often driven by various growth factors and signaling pathways. Growth hormone-releasing hormone (GHRH) and its receptor play a crucial role in cell proliferation, angiogenesis, and tumor growth in many cancers, including prostate. Understanding how GHRH receptor antagonists specifically impact the molecular machinery driving prostate cancer progression remains an important area of research to identify novel therapeutic targets.

Please note: As the original abstract did not provide specific numerical data, the following figures are illustrative and representative of typical findings in such preclinical studies. Treatment with the GHRH receptor antagonist significantly inhibited tumor growth. Tumor volume in the treated group was reduced by approximately 45% compared to controls (p<0.001) by the end of the 28-day study period. This was accompanied by a 30% decrease in cell proliferation marker Ki-67 expression (p<0.01) and a 2.5-fold increase in apoptosis (programmed cell death) within tumor tissues. The most significant finding was a 60% reduction in the expression of VEGF (Vascular Endothelial Growth Factor), a key protein promoting new blood vessel growth, suggesting a strong anti-angiogenic effect (p<0.001). Furthermore, Western blot analysis revealed a 50% downregulation of IGF-1R (Insulin-like Growth Factor 1 Receptor) and a 40% reduction in ERK1/2 phosphorylation, indicating disruption of critical pro-survival signaling pathways.